Grifols (GRFS) Common Equity (2009 - 2025)
Grifols' (GRFS) quarterly Common Equity came in at $8.9 billion in Q4 2025, up 40.78% YoY from $6.3 billion in Q4 2024, and up 40.78% on a QoQ basis from $6.3 billion in Q4 2024.
Grifols (GRFS) Common Equity (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Common Equity data on file, last reported at $8.9 billion in Q4 2025.
- Quarterly Common Equity rose 40.78% year-over-year to $8.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.9 billion (up 40.78% YoY) and the FY2025 annual result came in at $8.9 billion, up 31707.94% from the prior year.
- Common Equity improved to $8.9 billion in Q4 2025, from $6.3 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $8.9 billion in Q4 2025 to a low of $6.3 billion in Q4 2024.
- A 5-year average of $7.8 billion and a median of $8.1 billion in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity soared 1539.99% — and 2024, when it declined 22.23%.
- Tracing GRFS's Common Equity over 5 years: stood at $7.8 billion in 2021, then climbed by 3.73% to $8.1 billion in 2022, then decreased by 0.68% to $8.1 billion in 2023, then fell by 22.23% to $6.3 billion in 2024, then soared by 40.78% to $8.9 billion in 2025.
- The last three Common Equity figures came in at $8.9 billion (Q4 2025), $6.3 billion (Q4 2024), and $8.1 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.97 Bn | 633.21 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.43 Bn | 463.86 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 376.87 Bn | 369.73 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.36 Bn | 295.67 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.56 Bn | 252.66 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.01 Bn | 178.83 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Grifols | 5.44 Bn | 4.44 Bn | - | 8.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.85 Bn |
| Dec 31, 2024 | 6.29 Bn |
| Dec 31, 2023 | 8.08 Bn |
| Dec 31, 2022 | 8.14 Bn |
| Dec 31, 2021 | 7.85 Bn |
| Dec 31, 2020 | -544.88 Mn |
| Sep 30, 2020 | 8.30 Bn |
| Mar 31, 2020 | 7.96 Bn |
| Dec 31, 2019 | 7.58 Bn |
| Sep 30, 2019 | 5.89 Bn |
| Dec 31, 2018 | 5.36 Bn |
| Sep 30, 2018 | 4.82 Bn |
| Jun 30, 2018 | 4.74 Bn |
| Mar 31, 2018 | 5.99 Bn |
| Dec 31, 2017 | 4.28 Bn |
| Jun 30, 2017 | 3.94 Bn |
| Dec 31, 2016 | 4.03 Bn |
| Sep 30, 2016 | 3.94 Bn |
| Jun 30, 2016 | 3.86 Bn |
| Mar 31, 2016 | 3.64 Bn |